Here are three key details:
1. Dr. Milligan will also step down from the board of directors once his replacement is found.
2. Hs spent 28 years at Gilead and served as CEO for the past two years.
3. Dr. Milligan’s departure comes as the company struggles with falling sales and profit. Gilead’s profits were $5.65 billion in the second quarter of 2018, down 21 percent compared to $7.1 billion in 2017, according to MarketWatch.
More articles on GI and endoscopy:
GI leader to know: Dr. Justin Howard of University of Minnesota Medical Center
Exact Sciences, Lumendi & more — 4 GI company key notes
10 most-read GI stories in 2018
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.